Experimental hyperhomocysteinemia reduces bone quality in rats

Clinical Chemistry

Volumn 53, Issue 8, 2007, Pages 1455-1461

  Herrmann, Markus ^a   Wildemann, Britt ^b   Claes, Lutz ^c   Klohs, Stefan ^b   Ohnmacht, Michael ^c   Taban Shomal, Omid ^a   Hübner, Ulrich ^a   Pexa, Anette ^d   Umanskaya, Natalia ^a   Herrmann, Wolfgang ^a  

^a SAARLAND UNIVERSITY   (Germany)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^c UNIVERSITY OF ULM   (Germany)

^d DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; CARBOXY TERMINAL TELOPEPTIDE; HOMOCYSTEINE; METHIONINE; OSTEOCALCIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE FRAGILITY; BONE TURNOVER; COMPRESSION; CONTROLLED STUDY; DIETARY INTAKE; DISEASE ASSOCIATION; DISEASE SEVERITY; FEMALE; FEMUR NECK; HYPERHOMOCYSTEINEMIA; IN VIVO STUDY; LUMBAR SPINE; NONHUMAN; OSSIFICATION; OSTEOLYSIS; OSTEOPOROSIS; PROTEIN BLOOD LEVEL; RAT; RISK FACTOR;

ANIMALS; BIOLOGICAL MARKERS; COMPRESSIVE STRENGTH; FEMALE; FEMORAL FRACTURES; FEMUR; FRACTURES, COMPRESSION; HYPERHOMOCYSTEINEMIA; OSTEOGENESIS; OSTEOPOROSIS; RATS; RATS, WISTAR; RISK FACTORS;

RATTUS;

EID: 34547623576     PISSN: 00099147     EISSN: None     Source Type: Journal    
DOI: 10.1373/clinchem.2007.086272     Document Type: Article

References (30)

1. Walker-Bone K, Walter G, Cooper C. Recent developments in the epidemiology of osteoporosis. Curr Opin Rheumatol 2002;14:411-5.
2. Melton LJ III. Adverse outcomes of osteoporotic fractures in the general population. J Bone Miner Res 2003;18:1139-41.
3. Chrischilles E, Shireman T, Wallace R. Costs and health effects of osteoporotic fractures. Bone 1994;15:377-86.
4. Kanis JA, Jonsson B. Economic evaluation of interventions for osteoporosis. Osteoporos Int 2002;13:765-7.
5. Hodgson SF, Watts NB, Bilezikian JP, Clarke BL, Gray TK, Harris DW, et al. American Association of Clinical Endocrinologists medical guidelines for clinical practice for the prevention and treatment of postmenopausal osteoporosis: 2001 edition, with selected updates for 2003. Endocr Pract 2003;9:544-64.
6. van Meurs JB, Dhonukshe-Rutten RA, Pluijm SM, van der Klift M, de Jonge R, Lindemans J, et al. Homocysteine levels and the risk of osteoporotic fracture. N Engl J Med 2004;350:2033-41.
7. McLean RR, Jacques PF, Selhub J, Tucker KL, Samelson EJ, Broe KE, et al. Homocysteine as a predictive factor for hip fracture in older persons. N Engl J Med 2004;350:2042-9.
8. Sato Y, Iwamoto J, Kanoko T, Satoh K. Homocysteine as a predictive factor for hip fracture in elderly women with Parkinson's disease. Am J Med 2005;118:1250-5.
9. Dhonukshe-Rutten RA, Pluijm SM, de Groot LC, Lips P, Smit JH, van Staveren WA. Homocysteine and vitamin B12 status relate to bone turnover markers, broadband ultrasound attenuation, and fractures in healthy elderly people. J Bone Miner Res 2005;20:921-9.
10. Herrmann M, Kraenzlin M, Pape G, Sand-Hill M, Herrmann W. Relation between homocysteine and biochemical bone turnover markers and bone mineral density in peri- and post-menopausal women. Clin Chem Lab Med 2005;43:1118-23.
11. Bode MK, Laitinen P, Risteli J, Uusimaa P, Juvonen T. Atherosclerosis, type 1 collagen cross-linking and homocysteine. Atherosclerosis 2000;152:531-2.
12. Gerdhem P, Ivaska KK, Isaksson A, Pettersson K, Vaananen HK, Obrant KJ, et al. Associations between homocysteine, bone turnover, BMD, mortality, and fracture risk in elderly women. J Bone Miner Res 2007;22:127-34.
13. Stanger O, Herrmann W, Pietrzik K, Fowler B, Geisel J, Dierkes J, et al. DACH-LIGA Homocystein (German, Austrian and Swiss Homocysteine Society): consensus paper on the rational clinical use of homocysteine, folic acid and B vitamins in cardiovascular and thrombotic diseases: guidelines and recommendations. Clin Chem Lab Med 2003;41:1392-403.
14. Refsum H, Smith AD, Ueland PM, Nexo E, Clarke R, McPartlin J, et al. Facts and recommendations about total homocysteine determinations: an expert opinion. Clin Chem 2004;50:3-32.
15. Sato Y, Honda Y, Iwamoto J, Kanoko T, Satoh K. Effect of folate and mecobalamin on hip fractures in patients with stroke: a randomized controlled trial. JAMA 2005;293:1082-8.
16. Parfitt AM, Drezner MK, Glorieux FH, Kanis JA, Malluche H, Meunier PJ, et al. Bone histomorphometry: standardization of nomenclature, symbols, and units. Report of the ASBMR Histomorphometry Nomenclature Committee. J Bone Miner Res 1987;2:595-610.
17. Woo CW, Siow YL, Karmin O. Homocysteine activates cAMP-response element binding protein in HepG2 through cAMP/PKA signaling pathway. Arterioscler Thromb Vasc Biol 2006;26:1043-50.
18. Toue S, Kodama R, Amao M, Kawamata Y, Kimura T, Sakai R. Screening of toxicity biomarkers for methionine excess in rats. J Nutr 2006;136:1716S-21S.
19. Joseph J, Joseph L, Shekhawat NS, Devi S, Wang J, Melchert RB, et al. Hyperhomocysteinemia leads to pathological ventricular hypertrophy in normotensive rats. Am J Physiol 2003;285:H679-86.
20. Gram GC, Vollset SE, Ueland PM, Refsum H, Meyer HE, Tell GS. Plasma homocysteine, folate and vitamin B12 and the risk of hip fracture: The Hordaland Homocysteine Study. J Bone Miner Res 2007;22 (In press).
21. van Meurs JB, Uitterlinden AG. Homocysteine and fracture prevention. JAMA 2005;293:1121-2.
22. van der Meulen MC, Jepsen KJ, Mikic B. Understanding bone strength: size isn't everything. Bone 2001;29:101-4.
23. Tommasini SM, Nasser P, Schaffler MB, Jepsen KJ. Relationship between bone morphology and bone quality in male tibias: implications for stress fracture risk. J Bone Miner Res 2005;20:1372-80.
24. Cagnacci A, Baldassari F, Rivolta G, Arangino S, Volpe A. Relation of homocysteine, folate, and vitamin B12 to bone mineral density of postmenopausal women. Bone 2003;33:956-9.
25. Golbahar J, Hamidi A, Aminzadeh MA, Omrani GR. Association of plasma folate, plasma total homocysteine, but not methylenetetrahydrofolate reductase C667T polymorphism, with bone mineral density in postmenopausal Iranian women: a cross-sectional study. Bone 2004;35:760-5.
26. Morris MS, Jacques PF, Selhub J. Relation between homocysteine and B-vitamin status indicators and bone mineral density in older Americans. Bone 2005;37:234-42.
27. Seeman E. The structural basis of bone fragility in men. Bone 1999;25:143-7.
28. Gundberg CM. Osteocalcin. In: Eastell R, Baumann M, Hoyle N, Wieczorek L, eds. Bone Markers: Biochemical and Clinical Perspectives. London: Martin Dunitz Ltd., 2001:65-72.
29. Herrmann M, Widmann T, Herrmann W. Elevated serum homocysteine and McKusick's hypothesis of a disturbed collagen crosslinking: What do we really know? Bone 2006;39:1385-6.
30. Saito M, Fujii K, Marumo K. Degree of mineralization-related collagen crosslinking in the femoral neck cancellous bone in cases of hip fracture and controls. Calcif Tissue Int 2006;79:160-8.